

# About IAVI



Translating science  
into global health impact

**IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.**

## Key program areas

IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we're doing to help solve them.

### ▶ HIV

In 2022, 1.3 million people acquired HIV, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

- Advance the next generation of vaccines to prevent HIV acquisition by pairing sophisticated science with community-rooted research.
- Develop injectable antibodies that can prevent HIV acquisition for as long as six months with one dose.
- Partner with Africa to end HIV through ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement with the U.S. Agency for International Development through the U.S. President's Emergency Plan for AIDS Relief.

### ▶ Tuberculosis (TB)

About one quarter of the world's population is infected with the bacterium that causes TB; 10.6 million people are estimated to have developed TB disease in 2021, resulting in approximately 1.6 million deaths.

- Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

### ▶ Emerging Infectious Diseases

We need rapid, scalable vaccine technologies for diseases that pose public health and bio-terror threats.

- Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, and Sudan virus diseases, and COVID-19.

### ▶ Novel technologies and platforms

IAVI seeks to maximize the impact of novel technologies throughout our research portfolio so that innovations reach people in LMICs.

- Leverage our scientific, clinical, and access functions to improve access to innovative health solutions across disease areas.

### ▶ Product Development Center

IAVI's PDC bridges the "valley of death" in biomedical innovation development to help advance promising candidates from laboratory to clinic.

- Support for 53 biologics candidates to date, out of which 25 advanced to clinical trials.

## IAVI fast facts

More than 25 years of breakthrough vaccine and antibody research

~375 employees

Staff in seven countries:  
India, Kenya, Netherlands,  
South Africa, Uganda, U.K., U.S.

Labs in La Jolla, California; Brooklyn, New York;  
and Faridabad, India

2023 revenue: \$130.5M

Revenue breakdown:  
53.6% governments;  
44.1% foundations and individuals;  
2.3% other sources

501(c)(3) nonprofit organization

## Pipeline 2024–2026

IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges. Below is the pipeline as of June 2024. For the most updated list of IAVI-led candidates, go to [iavi.org/iavi-pipeline](https://iavi.org/iavi-pipeline).

IAVI products in development												
Candidate	2024				2025				2026			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
HIV vaccine candidates	Germline targeting preclinical antigen research											
	eOD-GT8 60mer + Core-g28v2 60mer mRNA*											
	eOD-GT8 60mer mRNA*											
	rVSVΔG-Env-HIV											
Passive immunization against HIV via bnAbs	Triple antibody combination product											
	Preclinical				Phase 1							
Emerging infectious diseases vaccine candidates	rVSVΔG-LASV-GPC											
	rVSVΔG-SUDV-GP											
	Preclinical				Phase 1 (IAVI C104)							
	rVSVΔG-SARS-CoV-2											
Tuberculosis (TB) vaccine candidates	MTBVAC**											
	mRNA-encoded TB antigens											

\* Germline targeting program.

\*\* Trials in adults and adolescents. Biofabri is leading clinical development of the candidate in infants (currently in a Phase 3 trial).

IAVI-supported candidates												
Candidate	2024				2025				2026			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
HIV vaccine candidates	BG505 GT1.1 gp140, adjuvanted (AS01B)											
	BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum)											
	BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum)											
	DNA-HIV-PT123, AIDSVAX®B/E; DNA-HIV-PT123, CN54gp140, MVA CMDR.CN54gp140; TAF/FTC; TDF/FTC											
GRAd networked T-cell epitope*												
MosM3.1, MosM3.2, MosM3.3, adjuvanted												
Mini-protein for COVID-19 prophylaxis	IPD-52520											

\* Trial in people living with HIV and people living without HIV in Zimbabwe and South Africa. ReiThera is the vaccine contract development and manufacturing organization. Ragon Institute developed the networked epitope vaccine insert.

## IAVI gratefully acknowledges the generous support provided by the following major funders:



As of July 2024